Description: HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.
Home Page: www.hlstherapeutics.com
HLS Technical Analysis
10 Carlson Court
Etobicoke,
ON
M9W 6L2
Canada
Phone:
647 495 9000
Officers
| Name | Title |
|---|---|
| Mr. Gregory David Gubitz B.A., L.L.B., LL.B | Co-Founder & Chairman |
| Mr. Gilbert Godin | Co-Founder, CEO & Director |
| Mr. Tim Hendrickson M.B.A. | Chief Financial Officer |
| Mr. Sanjiv Sharma | Chief Commercial Officer |
| Mr. Ryan C. Lennox B.A., J.D. | Sr. VP of Legal, HR & Compliance and Corp. Sec. |
| David Spence | Corp. Controller |
Exchange: TO
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 185.1852 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.026 |
| Price-to-Sales TTM: | 5.4252 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 92 |